Business Segments · Selling, general and administrative expenses
MedSurg and Neurotechnology: — Selling, general and administrative expenses
Stryker MedSurg and Neurotechnology: — Selling, general and administrative expenses decreased by 59.2% to $930M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 59.6%, from $2.3B to $930M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 11, 2026
Rolls up toSG&A
How to read this metric
A lower ratio of SG&A to revenue indicates higher operational efficiency and better scalability of the business model.
Detailed definition
Encompasses the overhead costs required to operate the MedSurg and Neurotechnology segment, including sales force commis...
Peer comparison
Standard operating expense metric for all public companies, comparable across the medical device industry.
Metric ID:
syk_segment_medsurg_and_neurotechnology_selling_general_and_administrative_expensesHistorical Data
37 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.51B | $1.6B | $1.75B | $1.71B | $641M | $1.54B | $641M | $1.46B | $641M | $1.68B | $641M | $1.78B | $733.5M | $1.71B | $733.5M | $1.71B | $733.5M | $1.91B | $733.5M | $1.84B | $763M | $1.83B | $775M | $1.89B | $780M | $2.12B | $885M | $2.3B | $859M | $2.08B | $984M | $2.05B | $972M | $2.23B | $1.04B | $2.28B | $930M |
| QoQ Change | — | +6.4% | +8.9% | -2.0% | -62.5% | +140.1% | -58.3% | +127.0% | -55.9% | +162.4% | -61.9% | +177.8% | -58.8% | +133.0% | -57.1% | +133.1% | -57.1% | +160.5% | -61.6% | +150.4% | -58.5% | +140.0% | -57.7% | +144.4% | -58.8% | +172.2% | -58.3% | +159.9% | -62.7% | +142.0% | -52.7% | +107.8% | -52.5% | +129.1% | -53.4% | +119.7% | -59.2% |
| YoY Change | — | — | — | — | — | +2.3% | -57.4% | -9.2% | -60.0% | -3.6% | -63.3% | +4.2% | -57.1% | +11.0% | -52.3% | +17.5% | -49.6% | +13.6% | -56.4% | +3.1% | -57.2% | +7.1% | -54.7% | +10.8% | -54.4% | +11.1% | -53.7% | +25.2% | -53.2% | +13.5% | -46.3% | +8.0% | -48.7% | +4.9% | -51.1% | -0.8% | -59.6% |
Range$641M – $2.3B
CAGR-5.2%
Avg YoY Growth-23.6%
Median YoY Growth-27.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's medsurg and neurotechnology: — selling, general and administrative expenses?
- Stryker (SYK) reported medsurg and neurotechnology: — selling, general and administrative expenses of $930M in Q1 2026.
- How has Stryker's medsurg and neurotechnology: — selling, general and administrative expenses changed year-over-year?
- Stryker's medsurg and neurotechnology: — selling, general and administrative expenses decreased by 59.6% year-over-year, from $2.3B to $930M.
- What does medsurg and neurotechnology: — selling, general and administrative expenses mean?
- The operating costs to sell products and manage the business segment, excluding production costs.